E. R. Khasanova

E. R. Khasanova

Auto-generated profile, based on publicly available information

E. R. Khasanova

Peoples' Friendship University of Russia (RUDN University)

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2019 in Kardiologiia
Verified
Journal Article
Open access
PDF file
ZKZh. D. Kobalava
Zh. D. Kobalava
NYN. V. Yeshniyazov
N. V. Yeshniyazov
VMVadim Medovchshikov
Vadim Medovchshikov
EKE. R. Khasanova
E. R. Khasanova
Type 2 diabetes mellitus (T2DM) has gone beyond the professional interests of one specialty. T2DM, cardiovascular (CV) diseases and chronic kidney disease, considered from the standpoint of a single cardio-reno-metabolic continuum, place a heavy economic burden on society. At the same time, the improvement of diagnostic methods and medical technologies led to distinct decrease in the frequency and mortality from a number of complications of T2DM, including myocardial infarction and stroke, but other states took their place. Thus, heart failure (HF) has taken the position of one of the most frequent complications with average prevalence of 24–40 % and significant predominance of HF with preserved ejection fraction (HFpEF). According to this paradigm, HFpEF is not a disease of diastolic dysfunction, but a systemic disease, the central element of which is impaired renal function. All this together has a potential value for choosing the optimal therapy. In recent years the results of specially designed studies assessing the CV-safety of antidiabetic drugs from the groups of dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like preptide-1 (GLP-1) receptor agonists and sodium – glucose co-transporter-2 (SGLT2) inhibitors have become known. These drugs, except for SGLT2 inhibitors, by their mechanism of action affecting insulin resistance and hyperglycemia, demonstrated neutral or negative result on the frequency of hospitalizations due to HF. The EMPA-REG OUTCOME study with SGLT2, which has a special insulin-independent mechanism of action, demonstrated not only the efficacy and CV-safety of the drug in the form of a decrease in CV mortality by 38 %, but also a decrease in hospitalizations for HF by 35 %. Further studies with SGLT2 inhibitors confirmed positive effect on HF, indicating a class effect of the drugs. The recently completed study DECLARE-TIMI 58 proved the advantages of using dapagliflozin for the primary and secondary prevention of HF. This review highlights the prevalence of HF in diabetes mellitus, a new concept of the pathophysiology of HF, the main groups of sugar-lowering drugs and their effect on CV outcomes, in particular on HF.

21 December 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZKZh. D. Kobalava
Zh. D. Kobalava
VTV. V. Tolkacheva
V. V. Tolkacheva
NBN. Kh. Bagmanova
N. Kh. Bagmanova
EKE. R. Khasanova
E. R. Khasanova
Aim.To assess the effectiveness and safety of therapy with fixed combination of amlodipine/indapamide (Arifam) in outpatients with arterial hypertension (AH) over 55 years old.Material and methods.We included 2217 patients in the observation — 692 (31%) men and 1521 (69%) women. Changes in the course of 3-month therapy of systolic and diastolic blood pressure (BP), the frequency of achievement of target BP levels (<140/90 mm Hg), responder rate during the clinical and ambulatory blood pressure measurement were evaluated and.Results.With the use of Arifam fixed combination 89,81% of patients achieved target BP level by the 3rd month of treatment, 73,77% of patients achieved positive response in 2 weeks, 94,88% of patients — after 1 month. According to the selfcontrol data, the target BP level (<135/85 mm Hg) was achieved in 79,47% of patients. The number of patients with pulse BP <60 mm Hg increased after 3 months of treatment to 81,97%. Also 48 (2,17%) patients discontinued participation; 6 (0,28%) patients — due to the development of adverse events.Conclusion.The ARBALET program has demonstrated high efficacy and tolerance of using Arifam fixed combination in outpatients over 55 years old with hypertension.

26 November 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
ZKZh. D. Kobalava
Zh. D. Kobalava
VMVadim Medovchshikov
Vadim Medovchshikov
NYN. B. Yeshniyazov
N. B. Yeshniyazov
EKE. R. Khasanova
E. R. Khasanova

1 January 2002
Verified
Journal Article
Closed access
MBM I Balabolkin
M I Balabolkin
EKE R Khasanova
E R Khasanova
TTT V Trukhina
T V Trukhina
VKV M Kreminskaia
V M Kreminskaia